Chiauranib
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects[1].
Product Specifications
CAS Number
1256349-48-0
Product Name Alternative
Ibcasertib; CS2164
UNSPSC
12352005
Hazard Statement
H302-H315-H319
Target
Aurora Kinase; c-Fms; c-Kit; Mitosis; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/chiauranib.html
Purity
99.28
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=CC=C1N)C2=C3C=CC(OC4=CC=NC5=CC(OC)=CC=C54)=CC3=CC=C2
Molecular Formula
C27H21N3O3
Molecular Weight
435.47
Precautions
P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Aurora B; PDGFRα; PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CIB3 sgRNA CRISPR Lentivector (Human) (Target 1)
Primate Albumin ELISA Kit (for Urine and Cell Samples)
Protein Tyrosine Phosphatase, Non-Receptor Type 2 Antibody
EIF4EBP2P-set siRNA/shRNA/RNAi Lentivector (Human)